(NASDAQ: SAVA) Cassava Sciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Cassava Sciences's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast SAVA's revenue for 2024 to be $8,645,042,200, with the lowest SAVA revenue forecast at $8,645,042,200, and the highest SAVA revenue forecast at $8,645,042,200.
In 2025, SAVA is forecast to generate $12,967,563,300 in revenue, with the lowest revenue forecast at $12,967,563,300 and the highest revenue forecast at $12,967,563,300.